Intellia Therapeutics, a leading biotechnology company, announced that its CRISPR-based treatment for a rare swelling ...

Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a ...

A phase 3 trial of Intellia Therapeutics’ in vivo gene-editing therapy lonvoguran ziclumeran (lonvo-z) has hit its primary ...

We'll know more about the company's medium-term prospects by the end of the year.

CRSP eyes a Q1 beat as rising Casgevy uptake, improving sales outlook and a strong Earnings ESP set the stage ahead of results.

For most of their lives, plants get their energy from photosynthesis. But during the seed to seedling stage, when they can't ...

The company's treatment for hereditary angioedema reduced attacks by 87% vs. placebo in a Phase 3 trial, clearing the way for ...

The company's strong cash position gives investors confidence in the gene-editing stock.

Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...

The findings position Intellia to bring to market the first “in vivo” gene editing medicine, though the therapy’s commercial ...

Intellia Therapeutics has reported the first-ever phase 3 results with an in vivo gene-editing therapy, hereditary angioedema ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $52.06, marking a +2.1% move from the previous day. This change outpaced the S&P 500's 0.49% loss on the day. Elsewhere, the Dow ...